Current status of rivaroxaban in elderly patients with pulmonary embolism (Review)

Song,Zi‑Kai; Cao,Hongyan; Wu,Haidi; Wei,Qi; Tang,Minglong; Yang,Shuo; Liu,Yang; Qin,Ling

doi:10.3892/etm.2020.8559

Current status of rivaroxaban in elderly patients with pulmonary embolism (Review)

Authors:
- Zi‑Kai Song
- Hongyan Cao
- Haidi Wu
- Qi Wei
- Minglong Tang
- Shuo Yang
- Yang Liu
- Ling Qin
View Affiliations

Affiliations: Department of Cardiology, The First Hospital of Jilin University, Changchun, Jilin 130000, P.R. China
Published online on: February 26, 2020 https://doi.org/10.3892/etm.2020.8559
Pages: 2817-2825
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute pulmonary embolism (PE) occurs with a high incidence rate in elderly patients, demonstrating complex clinical manifestations, as well as a difficult anticoagulant treatment strategy. Currently, there is limited understanding of the selection criteria for anticoagulant treatment in elderly patients with PE. In fact, the vitamin K antagonist warfarin, a commonly prescribed anticoagulant, has multiple disadvantages, including a narrow therapeutic range, unpredictable pharmacokinetics, multiple food and drug interactions and genetic polymorphisms resulting in poor response to this therapy; therefore, routine laboratory monitoring is required. Most elderly patients with PE fail to adhere to the treatment regimen or even discontinue it, and clinicians are equally hesitant to initiate oral anticoagulants in elderly patients with PE. This leads to a dilemma regarding the use of anticoagulation therapies and a worse prognosis for the patients. Rivaroxaban, a direct Xa factor inhibitor, has demonstrated considerable practical and clinical advantages, exhibits fast‑start action pharmacokinetic and pharmacodynamic characteristics, and has an enhanced predictable anticoagulant effect with fewer drug‑drug interactions. Based on randomized controlled trials and real‑world clinical practice, rivaroxaban has also been recognized as a safe and effective anticoagulant, and these advantages have improved the therapeutic compliance of elderly patients with PE. Thus, this review focused on the current status of rivaroxaban treatment for elderly patients with PE, and described its significance in changing the current anticoagulation treatment regimens for patients. It is expected that rivaroxaban will become a good choice for the treatment of PE in elderly patients.

View Figures

View References

1	Engbers MJ, van Hylckama Vlieg A and Rosendaal FR: Venous thrombosis in the elderly: Incidence, risk factors and risk groups. J Thromb Haemost. 8:2105–2112. 2010.PubMed/NCBI View Article : Google Scholar
2	Spencer FA, Gurwitz JH, Schulman S, Linkins LA, Crowther MA, Ginsberg JS, Lee AY, Saczynski JS, Anand S, Lessard D, et al: Venous thromboembolism in older adults: A community-based study. Am J Med. 127:530–537.e3. 2014.PubMed/NCBI View Article : Google Scholar
3	Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK and Olson RE: Venous thromboembolism according to age: The impact of an aging population. Arch Intern Med. 164:2260–2265. 2004.PubMed/NCBI View Article : Google Scholar
4	Karamichalakis N, Georgopoulos S, Vlachos K, Liatakis I, Efremidis M, Sideris A and Letsas KP: Efficacy and safety of novel anticoagulants in the elderly. J Geriatr Cardiol. 13:718–723. 2016.PubMed/NCBI View Article : Google Scholar
5	Sharma M, Cornelius VR, Patel JP, Davies JG and Molokhia M: Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: Systematic review and meta-analysis. Circulation. 132:194–204. 2015.PubMed/NCBI View Article : Google Scholar
6	Gallus A, Jackaman J, Tillett J, Mills W and Wycherley A: Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 2:1293–1296. 1986.PubMed/NCBI View Article : Google Scholar
7	Hirsh J: Low-molecular-weight heparin vs. Warfarin for prophylaxis against deep-vein thrombosis. N Engl J Med. 330(863)1994.PubMed/NCBI View Article : Google Scholar
8	Monreal M, Foz M and Audi L: Warfarin to prevent thromboembolism in chronic atrial fibrillation. Lancet. 1:720–721. 1989.PubMed/NCBI View Article : Google Scholar
9	Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S and Segers A: Einstein-DVT Dose-Ranging Study investigators: A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: The Einstein-DVT Dose-Ranging Study. Blood. 112:2242–2247. 2008.PubMed/NCBI View Article : Google Scholar
10	Scaglione F: New oral anticoagulants: Comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 52:69–82. 2013.PubMed/NCBI View Article : Google Scholar
11	EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, et al: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 363:2499–2510. 2010.PubMed/NCBI View Article : Google Scholar
12	EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, et al: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 366:1287–1297. 2012.PubMed/NCBI View Article : Google Scholar
13	Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, et al: 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 35:3033–3069. 2014.PubMed/NCBI View Article : Google Scholar
14	Mayr A, Klug G, Greulich S, Metzler B and Feuchtner G: Serpentine-like right atrial mass and fulminant bilateral pulmonary embolism during treatment with rivaroxaban. Int J Cardiovasc Imaging. 32:1001–1002. 2016.PubMed/NCBI View Article : Google Scholar
15	Menichetti M, Rosso S, Menegatti E and Pazzaglia M: Use of rivaroxaban in an elderly patient with intermediate-low early mortality risk due to pulmonary embolism: A case report. J Med Case Rep. 9(274)2015.PubMed/NCBI View Article : Google Scholar
16	Beckman MG, Hooper WC, Critchley SE and Ortel TL: Venous thromboembolism: A public health concern. Am J Prev Med. 38 (Suppl 4):S495–S501. 2010.PubMed/NCBI View Article : Google Scholar
17	Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR and Hammerstrom J: Incidence and mortality of venous thrombosis: A population-based study. J Thromb Haemost. 5:692–699. 2007.PubMed/NCBI View Article : Google Scholar
18	McRae S, Tran H, Schulman S, Ginsberg J and Kearon C: Effect of patient's sex on risk of recurrent venous thromboembolism: A meta-analysis. Lancet. 368:371–378. 2006.PubMed/NCBI View Article : Google Scholar
19	Spencer FA, Gore JM, Lessard D, Emery C, Pacifico L, Reed G, Gurwitz JH and Goldberg RJ: Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost. 100:780–788. 2008.PubMed/NCBI
20	Ageno W, Agnelli G, Imberti D, Moia M, Palareti G, Pistelli R, Rossi R and Verso M: MASTER Investigators: Risk factors for venous thromboembolism in the elderly: Results of the master registry. Blood Coagul Fibrinolysis. 19:663–667. 2008.PubMed/NCBI View Article : Google Scholar
21	Andreotti F, Rocca B, Husted S, Ajjan RA, ten Berg J, Cattaneo M, Collet JP, De Caterina R, Fox KA, Halvorsen S, et al: Antithrombotic therapy in the elderly: Expert position paper of the european society of cardiology working group on thrombosis. Eur Heart J. 36:3238–3249. 2015.PubMed/NCBI View Article : Google Scholar
22	Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM and Melton LJ III: Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med. 158:585–593. 1998.PubMed/NCBI View Article : Google Scholar
23	Kakkar VV, Howe CT, Flanc C and Clarke MB: Natural history of postoperative deep-vein thrombosis. Lancet. 2:230–232. 1969.PubMed/NCBI View Article : Google Scholar
24	Henriksson P, Westerlund E, Wallen H, Brandt L, Hovatta O and Ekbom A: Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: Cross sectional study. BMJ. 346(e8632)2013.PubMed/NCBI View Article : Google Scholar
25	Montecucco F and Mach F: Should we focus on ‘venous vulnerability’ instead of ‘plaque vulnerability’ in symptomatic atherosclerotic patients? Thromb Haemost. 106:995–996. 2011.
26	Gussoni G, Frasson S, La Regina M, Di Micco P and Monreal M: RIETE Investigators: Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res. 131:24–30. 2013.PubMed/NCBI View Article : Google Scholar
27	Clayton TC, Gaskin M and Meade TW: Recent respiratory infection and risk of venous thromboembolism: Case-control study through a general practice database. Int J Epidemiol. 40:819–827. 2011.PubMed/NCBI View Article : Google Scholar
28	Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, Green J and Reeves GK: Million Women Study Collaborators: Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 10:2277–2286. 2012.PubMed/NCBI View Article : Google Scholar
29	Johnson SA, Eleazer GP and Rondina MT: Pathogenesis, diagnosis, and treatment of venous thromboembolism in older adults. J Am Geriatr Soc. 64:1869–1878. 2016.PubMed/NCBI View Article : Google Scholar
30	Mohebali D, Kaplan D, Carlisle M, Supiano MA and Rondina MT: Alterations in platelet function during aging: Clinical correlations with thromboinflammatory disease in older adults. J Am Geriatr Soc. 62:529–535. 2014.PubMed/NCBI View Article : Google Scholar
31	van Hylckama Vlieg A and Rosendaal FR: High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost. 1:2677–2678. 2003.PubMed/NCBI View Article : Google Scholar
32	Oger E, Lacut K, Van Dreden P, Bressollette L, Abgrall JF, Blouch MT, Scarabin PY and Mottier D: High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly. Haematologica. 88:465–469. 2003.PubMed/NCBI
33	Yamamoto K, Takeshita K and Saito H: Plasminogen activator inhibitor-1 in aging. Semin Thromb Hemost. 40:652–659. 2014.PubMed/NCBI View Article : Google Scholar
34	Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, Guralnik JM and Longo DL: The origins of age-related proinflammatory state. Blood. 105:2294–2299. 2005.PubMed/NCBI View Article : Google Scholar
35	Mauritz GJ, Marcus JT, Westerhof N, Postmus PE and Vonk-Noordegraaf A: Prolonged right ventricular post-systolic isovolumic period in pulmonary arterial hypertension is not a reflection of diastolic dysfunction. Heart. 97:473–478. 2011.PubMed/NCBI View Article : Google Scholar
36	McIntyre KM and Sasaha AA: The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. Am J Cardiol. 28:288–294. 1971.PubMed/NCBI View Article : Google Scholar
37	Madhavan MV, Gersh BJ, Alexander KP, Granger CB and Stone GW: Coronary Artery Disease in Patients ≥80 Years of Age. J Am Coll Cardiol. 71:2015–2040. 2018.PubMed/NCBI View Article : Google Scholar
38	Lankhaar JW, Westerhof N, Faes TJ, Marques KM, Marcus JT, Postmus PE and Vonk-Noordegraaf A: Quantification of right ventricular afterload in patients with and without pulmonary hypertension. Am J Physiol Heart Circ Physiol. 291:H1731–H1737. 2006.PubMed/NCBI View Article : Google Scholar
39	Lankeit M, Jimenez D, Kostrubiec M, Dellas C, Hasenfuss G, Pruszczyk P and Konstantinides S: Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: A prospective validation study. Circulation. 124:2716–2724. 2011.PubMed/NCBI View Article : Google Scholar
40	Mehta NJ, Jani K and Khan IA: Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J. 145:821–825. 2003.PubMed/NCBI View Article : Google Scholar
41	Burrowes KS, Clark AR and Tawhai MH: Blood flow redistribution and ventilation-perfusion mismatch during embolic pulmonary arterial occlusion. Pulm Circ. 1:365–376. 2011.PubMed/NCBI View Article : Google Scholar
42	Larsson L, Grimby G and Karlsson J: Muscle strength and speed of movement in relation to age and muscle morphology. J Appl Physiol Respir Environ Exerc Physiol. 46:451–456. 1979.PubMed/NCBI View Article : Google Scholar
43	Olsen H and Lanne T: Reduced venous compliance in lower limbs of aging humans and its importance for capacitance function. Am J Physiol. 275:H878–H886. 1998.PubMed/NCBI View Article : Google Scholar
44	Migliacci R, Becattini C, Pesavento R, Davi G, Vedovati MC, Guglielmini G, Falcinelli E, Ciabattoni G, Dalla Valle F, Prandoni P, et al: Endothelial dysfunction in patients with spontaneous venous thromboembolism. Haematologica. 92:812–818. 2007.PubMed/NCBI View Article : Google Scholar
45	Chopard RP, Miranda Neto MH, Biazotto W and Molinari SL: Age-related changes in the human renal veins and their valves. Ital J Anat Embryol. 99:91–101. 1994.PubMed/NCBI
46	Bergan JJ, Schmid-Schonbein GW, Smith PD, Nicolaides AN, Boisseau MR and Eklof B: Chronic venous disease. N Engl J Med. 355:488–498. 2006.PubMed/NCBI View Article : Google Scholar
47	Mahmoodi BK, Gansevoort RT, Veeger NJ, Matthews AG, Navis G, Hillege HL and van der Meer J: Prevention of Renal and Vascular End-stage Disease (PREVEND) Study Group: Microalbuminuria and risk of venous thromboembolism. JAMA. 301:1790–1797. 2009.PubMed/NCBI View Article : Google Scholar
48	Carpentier P and Priollet P: Epidemiology of chronic venous insufficiency. Presse Med. 23:197–201. 1994.(In French). PubMed/NCBI
49	Miniati M, Prediletto R, Formichi B, Marini C, Di Ricco G, Tonelli L, Allescia G and Pistolesi M: Accuracy of clinical assessment in the diagnosis of pulmonary embolism. Am J Respir Crit Care Med. 159:864–871. 1999.PubMed/NCBI View Article : Google Scholar
50	Pollack CV, Schreiber D, Goldhaber SZ, Slattery D, Fanikos J, O'Neil BJ, Thompson JR, Hiestand B, Briese BA, Pendleton RC, et al: Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol. 57:700–706. 2011.PubMed/NCBI View Article : Google Scholar
51	Robert-Ebadi H and Righini M: Diagnosis and management of pulmonary embolism in the elderly. Eur J Intern Med. 25:343–349. 2014.PubMed/NCBI View Article : Google Scholar
52	Stein PD and Henry JW: Clinical characteristics of patients with acute pulmonary embolism stratified according to their presenting syndromes. Chest. 112:974–979. 1997.PubMed/NCBI View Article : Google Scholar
53	Song Z, Wu H, Cao H, Tang M, Yang S and Qin L: Nephrotic syndrome with acute pulmonary embolism in young adults: Two case reports. Medicine (Baltimore). 97(e11495)2018.PubMed/NCBI View Article : Google Scholar
54	Prandoni P, Lensing AW, Prins MH, Ciammaichella M, Perlati M, Mumoli N, Bucherini E, Visonà A, Bova C, Imberti D, et al: Prevalence of pulmonary embolism among patients hospitalized for syncope. N Engl J Med. 375:1524–1531. 2016.PubMed/NCBI View Article : Google Scholar
55	Le Gal G, Righini M, Roy PM, Meyer G, Aujesky D, Perrier A and Bounameaux H: Differential value of risk factors and clinical signs for diagnosing pulmonary embolism according to age. J Thromb Haemost. 3:2457–2464. 2005.PubMed/NCBI View Article : Google Scholar
56	Imberti D and Barillari G: eXperience VTE Italian Group: Real-Life Management of Venous Thromboembolism With Rivaroxaban: Results From EXperience VTE, an Italian Epidemiological Survey. Clin Appl Thromb Hemost. 24:241–247. 2018.PubMed/NCBI View Article : Google Scholar
57	Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A and ten Cate JW: Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 339:441–445. 1992.PubMed/NCBI View Article : Google Scholar
58	Columbus Investigators, Büller HR, Gent M, Gallus AS, Ginsberg J, Prins MH and Baildon R: Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 337:657–662. 1997.PubMed/NCBI View Article : Google Scholar
59	Eekels JJM, Althaus K, Bakchoul T, Kroll H, Kiefel V, Nazy I, Lee LS, Sachs U, Warkentin TE and Greinacher A: An international external quality assessment for laboratory diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost. 17:525–531. 2019.PubMed/NCBI View Article : Google Scholar
60	Toda A, Uehara S, Inoue T, Utoh M, Kusama T, Shimizu M, Uno Y, Mogi M, Sasaki E and Yamazaki H: Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19. Xenobiotica. 48:720–726. 2018.PubMed/NCBI View Article : Google Scholar
61	Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, et al: Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 11(21)2013.PubMed/NCBI View Article : Google Scholar
62	Lopez-Jimenez L, Montero M, Gonzalez-Fajardo JA, Arcelus JI, Suárez C, Lobo JL and Monreal M: RIETE Investigators: Venous thromboembolism in very elderly patients: Findings from a prospective registry (RIETE). Haematologica. 91:1046–1051. 2006.PubMed/NCBI
63	Lim W, Dentali F, Eikelboom JW and Crowther MA: Meta-analysis: Low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 144:673–684. 2006.PubMed/NCBI View Article : Google Scholar
64	Silverstein RL, Bauer KA, Cushman M, Esmon CT, Ershler WB and Tracy RP: Venous thrombosis in the elderly: More questions than answers. Blood. 110:3097–3101. 2007.PubMed/NCBI View Article : Google Scholar
65	Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, Acton RT and Allon M: Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 20:912–921. 2009.PubMed/NCBI View Article : Google Scholar
66	Mangoni AA and Jackson SH: Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. Br J Clin Pharmacol. 57:6–14. 2004.PubMed/NCBI View Article : Google Scholar
67	Garcia D, Regan S, Crowther M, Hughes RA and Hylek EM: Warfarin maintenance dosing patterns in clinical practice: Implications for safer anticoagulation in the elderly population. Chest. 127:2049–2056. 2005.PubMed/NCBI View Article : Google Scholar
68	Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF and Raskob GE: Aging and heparin-related bleeding. Arch Intern Med. 156:857–860. 1996.PubMed/NCBI
69	Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM and Palareti G: Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141 (Suppl 2):e44S–e88S. 2012.PubMed/NCBI View Article : Google Scholar
70	Cook LM, Kahn SR, Goodwin J and Kovacs MJ: Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost. 5:937–941. 2007.PubMed/NCBI View Article : Google Scholar
71	Barba R, Marco J, Martin-Alvarez H, Rondon P, Fernández-Capitan C, Garcia-Bragado F and Monreal M: RIETE investigators: The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: Findings from a prospective registry (RIETE). J Thromb Haemost. 3:856–862. 2005.PubMed/NCBI View Article : Google Scholar
72	Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, et al: The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 39:1330–1393. 2018.PubMed/NCBI View Article : Google Scholar
73	Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, et al: Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 358:2765–2775. 2008.PubMed/NCBI View Article : Google Scholar
74	Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, et al: Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 377:1319–1330. 2017.PubMed/NCBI View Article : Google Scholar
75	Geldhof V, Vandenbriele C, Verhamme P and Vanassche T: Venous thromboembolism in the elderly: Efficacy and safety of non-VKA oral anticoagulants. Thromb J. 12(21)2014.PubMed/NCBI View Article : Google Scholar
76	Greinacher A, Thiele T and Selleng K: Reversal of anticoagulants: An overview of current developments. Thromb Haemost. 113:931–942. 2015.PubMed/NCBI View Article : Google Scholar
77	van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M and Lensing AW: Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin. 30:829–837. 2014.PubMed/NCBI View Article : Google Scholar
78	Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, Zhuo DY, Huynh L and Nutescu EA: Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ. 17:52–64. 2014.PubMed/NCBI View Article : Google Scholar
79	Merli GJ, Hollander JE, Lefebvre P, Laliberté F, Raut MK, Germain G, Bookhart B and Pollack CV: Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin. J Med Econ. 19:84–90. 2016.PubMed/NCBI View Article : Google Scholar
80	Ho P, Brooy BL, Hayes L and Lim WK: Direct oral anticoagulants in frail older adults: A geriatric perspective. Semin Thromb Hemost. 41:389–394. 2015.PubMed/NCBI View Article : Google Scholar
81	Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, et al: Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 373:2413–2424. 2015.PubMed/NCBI View Article : Google Scholar